A few days ago, there was research showing that a clot removal technique might be the next step in certain stroke treatment. Click here to read about it.
One of the concerns about tissue plasminogen activator clotbuster - tPA - is a risk of bleeding. Now, though, research indicates the possibility that another drug might counters tPA risks:
A novel agent to mitigate adverse effects of stroke thrombolytics decreased the risk of intracranial hemorrhage and improved recovery, according to top-line results from a phase II trial.
Called THR-18, the investigational drug was associated with no cases of intracranial hemorrhage found on CT imaging 2 days after being given with tissue plasminogen activator (tPA) for acute ischemic stroke in the small trial ..., developer D-Pharm announced.Clot-busting tPA helped me but doesn't help everyone. Now, two studies show that better help might be on the way. Even with no absolute guarantees, these strike as good news for future stroke survival.